MAPT and Alzheimer disease: This explains the extensive phenotypic overlap of lvPPA with both later-stage typical Alzheimer’s disease and the posterior cortical atrophy variant, corroborated at post-mortem as well as on neuropsychological, CSF (raised phosphorylated tau levels, raised ratio of total tau to beta-amyloid1-42) and amyloid-PET case series [35, 70–72].